DK2656854T3 - Applications of an aromatic-cationic peptide - Google Patents

Applications of an aromatic-cationic peptide Download PDF

Info

Publication number: DK2656854T3
Authority: DK; Denmark
Prior art keywords: peptide; dmt1; dalda; mitochondria; mitochondrial
Prior art date: 2003-02-04

Application number

DK13178043.9T

Other languages

Danish (da)

English (en)

Inventor

Hazel H Szeto

Kesheng Zhao

Peter W Schiller

Original Assignee

Cornell Res Foundation Inc

Clinical Res Inst Of Montreal

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-04

Filing date

2004-02-03

Publication date

2015-07-06

2004-02-03 Application filed by Cornell Res Foundation Inc, Clinical Res Inst Of Montreal filed Critical Cornell Res Foundation Inc

2015-07-06 Application granted granted Critical

2015-07-06 Publication of DK2656854T3 publication Critical patent/DK2656854T3/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 80
208000028867 ischemia Diseases 0.000 claims description 36
230000010410 reperfusion Effects 0.000 claims description 14
210000005003 heart tissue Anatomy 0.000 claims description 12
230000000747 cardiac effect Effects 0.000 claims description 9
230000000302 ischemic effect Effects 0.000 claims description 5
238000002399 angioplasty Methods 0.000 claims description 4
210000004351 coronary vessel Anatomy 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
239000003527 fibrinolytic agent Substances 0.000 claims description 3
238000001356 surgical procedure Methods 0.000 claims description 3
206010002091 Anaesthesia Diseases 0.000 claims 1
230000037005 anaesthesia Effects 0.000 claims 1
210000003470 mitochondria Anatomy 0.000 description 51
FIAKHZXVLBNZLW-NFGXINMFSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CC=CC=C1 FIAKHZXVLBNZLW-NFGXINMFSA-N 0.000 description 50
101150002444 Slc11a2 gene Proteins 0.000 description 30
210000004027 cell Anatomy 0.000 description 29
230000002438 mitochondrial effect Effects 0.000 description 23
210000002216 heart Anatomy 0.000 description 22
SFVLTCAESLKEHH-WKAQUBQDSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 SFVLTCAESLKEHH-WKAQUBQDSA-N 0.000 description 19
238000007792 addition Methods 0.000 description 17
230000008965 mitochondrial swelling Effects 0.000 description 17
241000124008 Mammalia Species 0.000 description 15
230000000694 effects Effects 0.000 description 15
206010021143 Hypoxia Diseases 0.000 description 14
239000000872 buffer Substances 0.000 description 14
230000007954 hypoxia Effects 0.000 description 14
210000000056 organ Anatomy 0.000 description 14
102100030497 Cytochrome c Human genes 0.000 description 13
108010075031 Cytochromes c Proteins 0.000 description 13
PFYWPQMAWCYNGW-UHFFFAOYSA-M [6-(dimethylamino)-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]-dimethylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.COC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 PFYWPQMAWCYNGW-UHFFFAOYSA-M 0.000 description 12
201000010099 disease Diseases 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
238000000034 method Methods 0.000 description 10
102000051367 mu Opioid Receptors Human genes 0.000 description 10
238000011282 treatment Methods 0.000 description 10
108020001612 μ-opioid receptors Proteins 0.000 description 10
239000008148 cardioplegic solution Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 8
230000001964 calcium overload Effects 0.000 description 8
239000012981 Hank's balanced salt solution Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
-1 for instance Chemical class 0.000 description 7
239000000203 mixture Substances 0.000 description 7
208000015122 neurodegenerative disease Diseases 0.000 description 7
239000008188 pellet Substances 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
235000002639 sodium chloride Nutrition 0.000 description 7
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
108010036949 Cyclosporine Proteins 0.000 description 6
239000006172 buffering agent Substances 0.000 description 6
210000000170 cell membrane Anatomy 0.000 description 6
229960001265 ciclosporin Drugs 0.000 description 6
238000009472 formulation Methods 0.000 description 6
230000028161 membrane depolarization Effects 0.000 description 6
210000001700 mitochondrial membrane Anatomy 0.000 description 6
230000004770 neurodegeneration Effects 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000000243 solution Substances 0.000 description 6
241000700199 Cavia porcellus Species 0.000 description 5
229930105110 Cyclosporin A Natural products 0.000 description 5
238000009825 accumulation Methods 0.000 description 5
230000000202 analgesic effect Effects 0.000 description 5
230000006907 apoptotic process Effects 0.000 description 5
238000001218 confocal laser scanning microscopy Methods 0.000 description 5
210000000805 cytoplasm Anatomy 0.000 description 5
238000009826 distribution Methods 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
230000017074 necrotic cell death Effects 0.000 description 5
230000037050 permeability transition Effects 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
238000010791 quenching Methods 0.000 description 5
230000000171 quenching effect Effects 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000003381 stabilizer Substances 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
230000008961 swelling Effects 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000027829 mitochondrial depolarization Effects 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
230000010412 perfusion Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
208000017667 Chronic Disease Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000001490 Opioid Peptides Human genes 0.000 description 3
108010093625 Opioid Peptides Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000001640 apoptogenic effect Effects 0.000 description 3
108010033284 arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide Proteins 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
230000036770 blood supply Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 3
230000005284 excitation Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000007913 intrathecal administration Methods 0.000 description 3
210000002311 liver mitochondria Anatomy 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
208000002089 myocardial stunning Diseases 0.000 description 3
210000004165 myocardium Anatomy 0.000 description 3
239000003399 opiate peptide Substances 0.000 description 3
230000010627 oxidative phosphorylation Effects 0.000 description 3
230000035699 permeability Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000035479 physiological effects, processes and functions Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
210000002027 skeletal muscle Anatomy 0.000 description 3
210000002460 smooth muscle Anatomy 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
WBLZUCOIBUDNBV-UHFFFAOYSA-N 3-nitropropanoic acid Chemical compound OC(=O)CC[N+]([O-])=O WBLZUCOIBUDNBV-UHFFFAOYSA-N 0.000 description 2
208000030090 Acute Disease Diseases 0.000 description 2
108010009551 Alamethicin Proteins 0.000 description 2
FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
LGHSQOCGTJHDIL-UTXLBGCNSA-N alamethicin Chemical compound N([C@@H](C)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)N[C@H](C(=O)NC(C)(C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CO)CC=1C=CC=CC=1)C(C)C)C(=O)C(C)(C)NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(C)=O LGHSQOCGTJHDIL-UTXLBGCNSA-N 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229960004926 chlorobutanol Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000008828 contractile function Effects 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
239000000975 dye Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
230000007946 glucose deprivation Effects 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000000185 intracerebroventricular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
239000002756 mu opiate receptor agonist Substances 0.000 description 2
229940126487 mu opioid receptor agonist Drugs 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
231100000915 pathological change Toxicity 0.000 description 2
230000036285 pathological change Effects 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000002633 protecting effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
208000020431 spinal cord injury Diseases 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
230000008736 traumatic injury Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108020005199 Dehydrogenases Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
206010014498 Embolic stroke Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038678 Respiratory depression Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
102000037089 Uniporters Human genes 0.000 description 1
108091006293 Uniporters Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000000296 active ion transport Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940124326 anaesthetic agent Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000000576 arachnoid Anatomy 0.000 description 1
238000010009 beating Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000004289 cerebral ventricle Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
239000004927 clay Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000027721 electron transport chain Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000002490 intestinal epithelial cell Anatomy 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000013038 irreversible inhibitor Substances 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000001985 kidney epithelial cell Anatomy 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
230000004065 mitochondrial dysfunction Effects 0.000 description 1
230000004898 mitochondrial function Effects 0.000 description 1
230000006540 mitochondrial respiration Effects 0.000 description 1
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000000082 organ preservation Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
230000036284 oxygen consumption Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003761 preservation solution Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000036280 sedation Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Psychology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Pain & Pain Management (AREA)

DK13178043.9T 2003-02-04 2004-02-03 Applications of an aromatic-cationic peptide DK2656854T3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US44477703P	2003-02-04	2003-02-04
US53569004P	2004-01-08	2004-01-08
EP04707809.2A EP1599216B9 (en)	2003-02-04	2004-02-03	Methods for preventing mitochondrial permeability transition

Publications (1)

Publication Number	Publication Date
DK2656854T3 true DK2656854T3 (en)	2015-07-06

Family

ID=32853391

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK13178043.9T DK2656854T3 (en)	2003-02-04	2004-02-03	Applications of an aromatic-cationic peptide
DK14186875.2T DK2865385T3 (en)	2003-02-04	2004-02-03	Applications of the aromatic-cationic peptide
DK04707809.2T DK1599216T3 (da)	2003-02-04	2004-02-03	Fremgangsmåde til forebyggelse af mitokondriel permeabilitets-transition

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK14186875.2T DK2865385T3 (en)	2003-02-04	2004-02-03	Applications of the aromatic-cationic peptide
DK04707809.2T DK1599216T3 (da)	2003-02-04	2004-02-03	Fremgangsmåde til forebyggelse af mitokondriel permeabilitets-transition

Country Status (13)

Country	Link
US (8)	US7576061B2 (2)
EP (9)	EP1599216B9 (2)
JP (7)	JP4838114B2 (2)
CN (3)	CN104225574B (2)
AU (1)	AU2004209663B2 (2)
CA (1)	CA2515080C (2)
CY (2)	CY1114959T1 (2)
DK (3)	DK2656854T3 (2)
ES (3)	ES2540897T3 (2)
HU (1)	HUE027110T2 (2)
PT (2)	PT1599216E (2)
SI (1)	SI2656854T1 (2)
WO (1)	WO2004070054A2 (2)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1599216B9 (en) *	2003-02-04	2015-02-11	Cornell Research Foundation, Inc.	Methods for preventing mitochondrial permeability transition
PL2604286T3 (pl) *	2003-05-01	2015-03-31	Cornell Res Foundation Inc	Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
CA3024434A1 (en) *	2004-01-23	2005-08-11	Cornell Research Foundation, Inc.	Methods for reducing oxidative damage
CN104788540B (zh) *	2005-09-16	2019-10-18	科内尔研究基金会	用于减少cd36表达的方法
AU2014203126B2 (en) *	2005-09-16	2016-03-10	Cornell Research Foundation, Inc.	Methods for reducing cd36 expression
EP2712620A1 (en)	2008-02-07	2014-04-02	Cornell University	Methods for Preventing or Treating Insulin Resistance
EP3741381B1 (en)	2008-02-26	2024-04-24	Cornell University	A peptide for use for prevention and treatment of acute renal injury
DE102008061044A1 (de) *	2008-12-11	2010-06-17	Henkel Ag & Co. Kgaa	Zusammensetzung mit antioxidativ wirksamen Peptiden
US20100331265A1 (en) *	2009-03-20	2010-12-30	Tompkins Ronald G	Methods for the prevention and treatment of burn injuries and secondary complications
WO2011019809A1 (en) *	2009-08-12	2011-02-17	Cornell University	Methods for preventing or treating metabolic syndrome
ES2964555T3 (es)	2009-08-24	2024-04-08	Stealth Biotherapeutics Inc	Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2011044044A1 (en) *	2009-10-05	2011-04-14	Cornell University	Methods for the prevention or treatment of heart failure
EP3266462A1 (en) *	2009-12-31	2018-01-10	Stealth Peptides International, Inc.	Methods for performing a coronary artery bypass graft procedure
EP3090754A1 (en) *	2009-12-31	2016-11-09	Stealth Peptides International, Inc.	Methods for the prevention or treatment of vessel occlusion injury
CA2787331A1 (en) *	2010-01-25	2011-07-28	Hazel H. Szeto	Aromatic-cationic peptides and uses of same
JP2013521231A (ja) *	2010-02-26	2013-06-10	ユニバーシティオブフロリダリサーチファウンデーションインコーポレイテッド	ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
EP3375449A1 (en) *	2010-03-15	2018-09-19	Stealth Peptides International, Inc.	Combination therapies using cyclosporine and aromatic cationic peptides
US20110245182A1 (en)	2010-04-06	2011-10-06	Perricone Nicholas V	Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en)	2010-04-06	2011-10-06	Perricone Nicholas V	Topical Uses of Szeto-Schiller Peptides
EP3290433A1 (en) *	2010-05-03	2018-03-07	Stealth Peptides International, Inc.	Aromatic-cationic peptides and uses of same
WO2014137496A1 (en) *	2013-03-08	2014-09-12	The Administrators Of The Tulane Educational Fund	Mu opioid receptor agonist analogs of the endomorphins
EP2590664B1 (en) *	2010-07-09	2019-03-27	Stealth Peptides International, Inc.	Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
US20160176930A1 (en)	2010-07-09	2016-06-23	The Administrators Of The Tulane Educational Fund	Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en)	2010-09-30	2012-04-05	Perricone Nicholas V	Topical Anesthetic Uses of Szeto-Schiller Peptides
EP3108975A1 (en) *	2011-03-24	2016-12-28	Cornell University	Aromatic-cationic peptides and uses of same
WO2013043580A2 (en)	2011-09-19	2013-03-28	Gencia Corporation	Modified creatine compounds
CN106913860A (zh)	2011-09-29	2017-07-04	梅约医学教育与研究基金会	芳族阳离子肽和使用它们的方法
HK1201443A1 (en) *	2011-10-17	2015-09-04	Cornell University	Aromatic-cationic peptides and uses of same
EP2788013A4 (en) *	2011-12-09	2015-08-19	Stealth Peptides Int Inc	AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
CN104271146A (zh)	2012-03-30	2015-01-07	康肽德生物医药技术有限公司	用于预防和治疗神经病的方法和组合物
JP2015529655A (ja) *	2012-08-02	2015-10-08	ステルスペプチドズインターナショナルインコーポレイテッド	アテローム性硬化症の処置方法
AU2013334788A1 (en) *	2012-10-22	2015-06-04	Henry Ford Health Systems	Methods for reducing risks associated with heart failure and factors associated therewith
ES2755134T3 (es)	2013-03-01	2020-04-21	Stealth Biotherapeutics Corp	Métodos para el tratamiento de enfermedad mitocondrial
US9687519B2 (en)	2013-03-01	2017-06-27	Stealth Biotherapeutics Corp	Methods and compositions for the prevention or treatment of barth syndrome
EP2989120A4 (en)	2013-04-25	2017-04-19	Carmel-Haifa University Economic Corp.	Synthetic anti-inflammatory peptides and use thereof
CA2916977A1 (en)	2013-06-26	2014-12-31	Stealth Biotherapeutics Corp	Methods and compositions for detecting and diagnosing diseases and conditions
CA2919992C (en) *	2013-08-01	2022-08-09	Stealth Biotherapeutics Corp	Methods and compositions for preventing or treating leber's hereditary optic neuropathy
WO2015017861A1 (en)	2013-08-02	2015-02-05	Stealth Peptides International, Inc.	Methods and compositions for the prevention and treatment of friedreich's ataxia
EP3052115A4 (en) *	2013-09-30	2017-09-27	Cornell University	Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
CN106536056B (zh)	2014-06-13	2021-07-16	儿童医学中心公司	分离线粒体的产品和方法
EP3160984B1 (en)	2014-06-25	2021-04-14	Flamma S.P.A.	Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016001042A1 (en)	2014-06-30	2016-01-07	Flamma S.P.A.	Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) *	2014-07-01	2016-01-07	Stealth Biotherapeutics Corp	Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) *	2014-09-25	2016-08-24	中山大学	Wry三肽在制备治疗阿尔茨海默症药物中的用途
EP3212194A4 (en)	2014-10-29	2018-06-20	University Of Maryland	Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) *	2015-07-23	2017-01-26	Salk Institute For Biological Studies	Prevention and treatment of aging and neurodegenerative diseases
CA3006698A1 (en) *	2015-11-30	2017-06-08	Peter Schiller	Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017124037A1 (en)	2016-01-15	2017-07-20	The Children's Medical Center Corporation	Therapeutic use of mitochondria and combined mitochondrial agents
CA3017359A1 (en)	2016-03-11	2017-09-14	Scott M. Duncan	Crystalline salt forms
WO2017180535A1 (en)	2016-04-11	2017-10-19	Carnot, Llc	Chiral peptides
KR20190088520A (ko)	2016-11-30	2019-07-26	주식회사 다이셀	촬상 장치용 렌즈 모듈 및 그의 제조 방법
US11034724B2 (en)	2017-04-05	2021-06-15	Stealth Biotherapeutics Corp.	Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
WO2019033330A1 (en)	2017-08-17	2019-02-21	Xw Laboratories, Inc.	PREPARATION AND USES OF DERIVATIVES TRACERS OF OXYGEN REACTIVE SPECIES
EP3679051B1 (en)	2017-09-04	2021-12-29	XWPharma Ltd.	Preparation and use of reactive oxygen species scavenger
JP6958860B2 (ja) *	2017-11-07	2021-11-02	学校法人自治医科大学	ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en)	2018-01-26	2020-06-09	Stealth Biotherapeutics Corp.	Crystalline bis- and tris-hydrochloride salt of elamipretide
IL284006B2 (en) *	2018-12-18	2024-12-01	Stealth Biotherapeutics Corp	Mitochondria-targeting peptides
WO2020222866A1 (en) *	2019-05-02	2020-11-05	Children's Medical Center Corporation	Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
EP3771467A1 (en)	2019-07-30	2021-02-03	Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau	Ss-31 for the prevention and/or treatment of aneurysm
CN116390723B (zh) *	2020-09-09	2024-12-31	社会利益网络公司	用于将生物素递送至线粒体的方法和组合物
CN117881411A (zh)	2021-06-01	2024-04-12	艾迪雅生物有限责任公司	用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en)	1988-06-30	1997-02-11	Astra Ab	Dermorphin analogs having pharmacological activity
SG64368A1 (en)	1988-06-30	1999-04-27	Astra Ab	Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5670617A (en) *	1989-12-21	1997-09-23	Biogen Inc	Nucleic acid conjugates of tat-derived transport polypeptides
AU659795B2 (en) *	1990-01-17	1995-06-01	Regents Of The University Of California, The	Composition to improve survival of biological materials
US5858784A (en)	1991-12-17	1999-01-12	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en)	1992-06-11	1997-10-07	Alkermes, Inc.	Composition for sustained release of non-aggregated erythropoietin
US5716644A (en)	1992-06-11	1998-02-10	Alkermes, Inc.	Composition for sustained release of non-aggregated erythropoietin
IS4261A (is)	1994-02-21	1995-08-22	Astra Aktiebolag	Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) *	1995-06-09	2003-12-15	Hisamitsu Pharmaceutical Co	Matrix für iontophorese
US5849761A (en) *	1995-09-12	1998-12-15	Regents Of The University Of California	Peripherally active anti-hyperalgesic opiates
DE69722258T2 (de) *	1996-10-07	2004-03-18	Eli Lilly And Co., Indianapolis	Neue verbindungen nutlich als neuroschützende mittel
US5885958A (en) *	1997-03-25	1999-03-23	Administrators Of The Tulane Educational Fund	Mu-opiate receptor peptides
US5989463A (en)	1997-09-24	1999-11-23	Alkermes Controlled Therapeutics, Inc.	Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) *	1997-12-10	1999-06-17	Washington University	Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) *	1998-04-24	1999-11-04	Mitokor	Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) *	1998-08-31	2002-10-29	Pro-Neuron, Inc.	Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en)	1998-12-23	2001-06-12	Amgen Inc.	Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) *	1999-03-10	1999-05-05	Adprotech Plc	Novel compound formulations and methods of delivery
SE9900961D0 (sv)	1999-03-16	1999-03-16	Astra Ab	Novel compounds
DE60042338D1 (de) *	1999-10-04	2009-07-16	Univ New Jersey Med	TAR RNA bindende Peptide
US6759520B1 (en) *	1999-10-28	2004-07-06	The New England Medical Center Hospitals, Inc.	Chimeric analgesic peptides
US20050192215A1 (en)	2000-01-21	2005-09-01	Malabika Ghosh	Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) *	2000-07-18	2009-03-03	Cornell Research Foundation	Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) *	2000-09-12	2005-05-31	University Of Kentucky Research Foundation	Protection against ischemia and reperfusion injury
EP1339668A2 (en) *	2000-11-28	2003-09-03	Guilford Pharmaceuticals Inc.	Bisubstituted carbocyclic cyclophilin binding compounds and theirus
US6545097B2 (en) *	2000-12-12	2003-04-08	Scimed Life Systems, Inc.	Drug delivery compositions and medical devices containing block copolymer
US6656971B2 (en) *	2001-01-25	2003-12-02	Guilford Pharmaceuticals Inc.	Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20030077826A1 (en) *	2001-02-02	2003-04-24	Lena Edelman	Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
WO2002066095A2 (en) *	2001-02-16	2002-08-29	Cordis Corporation	Method of balloon catheter stent delivery system with ridges
AU2002252372A1 (en) *	2001-03-16	2002-10-03	Sts Biopolymers, Inc.	Stent with medicated multi-layer hydrid polymer coating
JPWO2002102833A1 (ja) *	2001-06-15	2004-09-30	千寿製薬株式会社	新規エンドモルフィン誘導体
EP1599216B9 (en) *	2003-02-04	2015-02-11	Cornell Research Foundation, Inc.	Methods for preventing mitochondrial permeability transition
CN101440124B (zh) *	2003-02-04	2012-07-18	科内尔研究基金会	用于防止线粒体通透性改变的方法
PL2604286T3 (pl)	2003-05-01	2015-03-31	Cornell Res Foundation Inc	Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
JP2005005762A (ja) *	2003-06-09	2005-01-06	Fujitsu Ltd	送信電力制御方法及び装置
WO2005032481A2 (en)	2003-09-30	2005-04-14	Scios Inc.	Quinazoline derivatives as medicaments
CA3024434A1 (en) *	2004-01-23	2005-08-11	Cornell Research Foundation, Inc.	Methods for reducing oxidative damage
CN104788540B (zh)	2005-09-16	2019-10-18	科内尔研究基金会	用于减少cd36表达的方法

2004
- 2004-02-03 EP EP04707809.2A patent/EP1599216B9/en not_active Expired - Lifetime
- 2004-02-03 CA CA2515080A patent/CA2515080C/en not_active Expired - Lifetime
- 2004-02-03 EP EP11009660.9A patent/EP2491943B1/en not_active Expired - Lifetime
- 2004-02-03 EP EP17192437.6A patent/EP3305313A1/en not_active Withdrawn
- 2004-02-03 CN CN201410412683.1A patent/CN104225574B/zh not_active Expired - Lifetime
- 2004-02-03 AU AU2004209663A patent/AU2004209663B2/en not_active Expired
- 2004-02-03 EP EP14186875.2A patent/EP2865385B1/en not_active Expired - Lifetime
- 2004-02-03 ES ES13178043.9T patent/ES2540897T3/es not_active Expired - Lifetime
- 2004-02-03 CN CN201210177633.0A patent/CN102784383B/zh not_active Expired - Lifetime
- 2004-02-03 EP EP16192437.8A patent/EP3144009A1/en not_active Withdrawn
- 2004-02-03 DK DK13178043.9T patent/DK2656854T3/en active
- 2004-02-03 US US10/771,232 patent/US7576061B2/en not_active Expired - Lifetime
- 2004-02-03 HU HUE13178043A patent/HUE027110T2/en unknown
- 2004-02-03 PT PT47078092T patent/PT1599216E/pt unknown
- 2004-02-03 EP EP20210900.5A patent/EP3842055A1/en active Pending
- 2004-02-03 DK DK14186875.2T patent/DK2865385T3/en active
- 2004-02-03 EP EP18199147.2A patent/EP3479838A1/en not_active Withdrawn
- 2004-02-03 PT PT131780439T patent/PT2656854E/pt unknown
- 2004-02-03 ES ES04707809T patent/ES2436011T3/es not_active Expired - Lifetime
- 2004-02-03 ES ES14186875.2T patent/ES2605504T3/es not_active Expired - Lifetime
- 2004-02-03 JP JP2006503317A patent/JP4838114B2/ja not_active Expired - Lifetime
- 2004-02-03 CN CN2012100218642A patent/CN102617706A/zh active Pending
- 2004-02-03 EP EP20130178043 patent/EP2656854B1/en not_active Expired - Lifetime
- 2004-02-03 WO PCT/US2004/003193 patent/WO2004070054A2/en not_active Ceased
- 2004-02-03 EP EP19207802.0A patent/EP3659618A1/en not_active Withdrawn
- 2004-02-03 SI SI200432258T patent/SI2656854T1/sl unknown
- 2004-02-03 DK DK04707809.2T patent/DK1599216T3/da active
2006
- 2006-06-30 US US11/427,804 patent/US7718620B2/en active Active
2010
- 2010-04-02 US US12/753,403 patent/US20100190718A1/en not_active Abandoned
- 2010-10-28 JP JP2010241738A patent/JP5775285B2/ja not_active Expired - Lifetime
2011
- 2011-09-28 US US13/247,648 patent/US8404646B2/en not_active Expired - Fee Related
2013
- 2013-02-27 US US13/778,994 patent/US8957030B2/en not_active Expired - Lifetime
- 2013-09-03 JP JP2013182343A patent/JP5837542B2/ja not_active Expired - Lifetime
2014
- 2014-01-24 CY CY20141100064T patent/CY1114959T1/el unknown
- 2014-10-01 JP JP2014202889A patent/JP6126059B2/ja not_active Expired - Lifetime
2015
- 2015-01-13 US US14/595,946 patent/US20150359838A1/en not_active Abandoned
- 2015-07-06 JP JP2015135207A patent/JP6166312B2/ja not_active Expired - Lifetime
- 2015-08-03 CY CY20151100675T patent/CY1116575T1/el unknown
2017
- 2017-02-15 JP JP2017025764A patent/JP2017095519A/ja active Pending
2019
- 2019-01-08 JP JP2019001256A patent/JP2019089773A/ja active Pending
- 2019-09-12 US US16/569,573 patent/US20200038472A1/en not_active Abandoned
2022
- 2022-02-10 US US17/668,744 patent/US20230293624A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK2865385T3 (en)	2016-12-19
JP6126059B2 (ja)	2017-05-10
EP2865385A1 (en)	2015-04-29
AU2004209663B2 (en)	2009-01-15
US20130244957A1 (en)	2013-09-19
JP5775285B2 (ja)	2015-09-09
EP3144009A1 (en)	2017-03-22
WO2004070054A2 (en)	2004-08-19
EP3842055A1 (en)	2021-06-30
JP6166312B2 (ja)	2017-07-19
JP2011026346A (ja)	2011-02-10
US7718620B2 (en)	2010-05-18
US20040248808A1 (en)	2004-12-09
US20150359838A1 (en)	2015-12-17
PT2656854E (pt)	2015-09-03
JP2015180693A (ja)	2015-10-15
EP2491943B1 (en)	2018-10-10
CA2515080C (en)	2012-04-10
WO2004070054A3 (en)	2005-04-14
CY1114959T1 (el)	2016-12-14
EP2491943A2 (en)	2012-08-29
HK1131995A1 (en)	2010-02-12
DK1599216T3 (da)	2013-12-09
ES2436011T3 (es)	2013-12-26
EP1599216A4 (en)	2009-11-11
ES2605504T3 (es)	2017-03-14
HK1204999A1 (en)	2015-12-11
HK1190930A1 (en)	2014-07-18
US20070027087A1 (en)	2007-02-01
HK1178794A1 (en)	2013-09-19
ES2540897T3 (es)	2015-07-14
CN102617706A (zh)	2012-08-01
US20100190718A1 (en)	2010-07-29
PT1599216E (pt)	2013-12-17
AU2004209663A1 (en)	2004-08-19
JP2013249313A (ja)	2013-12-12
US8404646B2 (en)	2013-03-26
JP4838114B2 (ja)	2011-12-14
SI2656854T1 (sl)	2015-09-30
EP2656854A1 (en)	2013-10-30
HK1209652A1 (en)	2016-04-08
US8957030B2 (en)	2015-02-17
CY1116575T1 (el)	2017-03-15
EP2491943A3 (en)	2013-01-23
CN102784383A (zh)	2012-11-21
HK1090571A1 (en)	2006-12-29
CA2515080A1 (en)	2004-08-19
HUE027110T2 (en)	2016-08-29
US20200038472A1 (en)	2020-02-06
AU2004209663A2 (en)	2004-08-19
EP1599216B1 (en)	2013-11-06
JP2019089773A (ja)	2019-06-13
US20230293624A1 (en)	2023-09-21
EP2656854B1 (en)	2015-05-20
CN102784383B (zh)	2014-09-17
JP2006516652A (ja)	2006-07-06
JP2015007127A (ja)	2015-01-15
CN104225574A (zh)	2014-12-24
EP1599216A2 (en)	2005-11-30
EP3659618A1 (en)	2020-06-03
EP3479838A1 (en)	2019-05-08
EP1599216B9 (en)	2015-02-11
EP2865385B1 (en)	2016-11-16
US20120021970A1 (en)	2012-01-26
EP3305313A1 (en)	2018-04-11
JP2017095519A (ja)	2017-06-01
CN104225574B (zh)	2017-01-11
US7576061B2 (en)	2009-08-18
JP5837542B2 (ja)	2015-12-24

Publication	Publication Date	Title
DK2656854T3 (en)	2015-07-06	Applications of an aromatic-cationic peptide
HK1190930B (en)	2016-03-18	Uses of aromatic-cationic peptide
HK1209652B (en)	2018-02-02	Uses of aromatic-cationic peptide
HK1235008A1 (en)	2018-03-02	Uses of aromatic-cationic peptide
HK1175106A (en)	2013-06-28	Methods for preventing mitochondrial permeability transition
HK1174643A (en)	2013-06-14	Methods for preventing mitochondrial permeability transition
HK1178794B (en)	2015-01-30	Methods for preventing mitochondrial permeability transition
HK1204999B (en)	2018-03-02	Methods for preventing mitochondrial permeability transition